Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.” ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its pipeline may one day add another $12 billion in sales each year.

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. See ...

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD stock is a strong buy.

Britain's Volex jumped over 20% on Thursday after the power and data transmission products maker reported double-digit growth in annual revenue and profit, buoyed by strong EV demand and higher North ...

New York’s legal marijuana habit is getting bigger, to the tune of $1.7 billion in sales to date since the regulated market ...

Total Sales: $970.5 million, a 19.5% increase from the previous year. Comparable Sales Increase: 7.1%, driven by a 6.2% increase in transactions and a 0.9% increase in ticket size. Adjusted Gross ...

PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance ...

Pipeline tells the story of five professional divers who were tasked with repairing an undersea oil pipe off the coast of Trinidad and Tobago in February 2022.

Capital Appreciation's annual results reveal significant growth in its Payments and Software divisions, with a notable ...

India's real estate revival has gained momentum, with large developers experiencing strong pre-sales, rising cash flows, and ...